Racquel Brockington
Family Medicine · Lansing, MINPI 1205955929
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 13.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $841 and has fallen 63.8% since, to $305 in 2025.
Across 72 payments — averaging $21.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$206
- Teva Pharmaceuticals USA, Inc.$179
- Sunovion Pharmaceuticals Inc.$176
- GSK$162
- Vanda Pharmaceuticals Inc.$146
- Amgen$84
- plus $623 from 17 others
What the payments were for
- Food & beverage$1,576100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 7 | $206 |
| Teva Pharmaceuticals USA, Inc. | 7 | $179 |
| Sunovion Pharmaceuticals Inc. | 8 | $176 |
| GSK | 6 | $162 |
| Vanda Pharmaceuticals Inc. | 5 | $146 |
| Amgen | 5 | $84 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $74 |
| Otsuka America Pharmaceutical, Inc. | 4 | $73 |
| Neurocrine Biosciences, Inc. | 3 | $70 |
| Pfizer | 4 | $69 |
| Novo Nordisk | 4 | $54 |
| Grifols USA, LLC | 2 | $48 |
| Alkermes, Inc. | 2 | $40 |
| AstraZeneca | 3 | $37 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Redhill Biopharma Inc. | 1 | $22 |
| Insulet Corporation | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Exact Sciences | 1 | $16 |
| Viiv Healthcare Company | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Novartis | 1 | $16 |
| Mylan Specialty L.p. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$125
- VRAYLAR$101
How this compares
$1,576 in reported general payments places this provider in the 75th percentile of 3,945 family medicine providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 12 | $12,566 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 14 | $299 |
| Atorvastatin Calcium | 28 | $190 |
| Amlodipine Besylate | 36 | $120 |
| Losartan Potassium | 16 | $98 |
| Lisinopril | 16 | $68 |
| Metformin Hcl | 13 | $33 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Lansing
- Farhan BhattiLansing$230K
- Laurie RozekLansing$86K
- Amy TrinhLansing$19K
- Rosemary RoperLansing$17K
- Mark SchaarLansing$16K
- Loren ChudlerSouthfield$1.3M
- Paul BensonBerkley$779K
- Matt RosenbergJackson$550K
- Steve LasaterSaint Johns$291K
- Mary DagenGrand Rapids$265K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.